SCHEMBL30730675

SCHEMBL30730675

Cn1ncnc1CC(=O)N1CCC(n2nnc(-c3ccc(F)c(Cl)c3)n2)CC1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 2/20 0.36
HSD11B1 P28845 1/20 0.35
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
DRD3 P35462 1/20 0.35
GRIN2B Q13224 3/20 0.35
CALCRL Q16602 1/20 0.34
LMNA P02545 2/20 0.34
RAB9A P51151 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
KMT2A Q03164 1/20 0.34
UGCG Q16739 1/20 0.33
CCR3 P51677 1/20 0.33
AOC3 Q16853 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730568 0.93 CCR3 (0.40) ENPP2HSD11B1DRD2DRD4DRD3
SCHEMBL30730526 0.92 KCNJ6 (0.39) ENPP2DRD2DRD4DRD3GRIN2B
SCHEMBL30730648 0.92 CALCRL (0.40) ENPP2HSD11B1DRD2DRD4DRD3
SCHEMBL30730500 0.89 DRD2 (0.41) ENPP2HSD11B1DRD2DRD4DRD3
SCHEMBL30730597 0.88 MAPK1 (0.44) DRD2DRD4DRD3LMNARAB9A
SCHEMBL30730669 0.83 LMNA (0.41) DRD2DRD4DRD3LMNARAB9A
SCHEMBL30730598 0.83 LMNA (0.53) LMNAALOX15TSHRMAPK1MEN1
SCHEMBL30730538 0.76 TSHR (0.53) LMNAALOX15TSHRMAPK1MEN1
SCHEMBL30730586 0.75 LMNA (0.51) LMNAALOX15TSHRMAPK1ALDH1A1
SCHEMBL30730617 0.75 LMNA (0.55) LMNAALOX15TSHRMAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 ENPP2 591/4885HSD11B1 235/4885DRD2 3525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.